These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26257061)

  • 41. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts.
    Mills KA; Quinn JM; Roach ST; Palisoul M; Nguyen M; Noia H; Guo L; Fazal J; Mutch DG; Wickline SA; Pan H; Fuh KC
    Sci Rep; 2019 Mar; 9(1):4762. PubMed ID: 30886159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.
    Vajkoczy P; Knyazev P; Kunkel A; Capelle HH; Behrndt S; von Tengg-Kobligk H; Kiessling F; Eichelsbacher U; Essig M; Read TA; Erber R; Ullrich A
    Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5799-804. PubMed ID: 16585512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
    Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
    Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
    Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
    Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
    Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
    Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.
    Paccez JD; Vasques GJ; Correa RG; Vasconcellos JF; Duncan K; Gu X; Bhasin M; Libermann TA; Zerbini LF
    Oncogene; 2013 Feb; 32(6):689-98. PubMed ID: 22410775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
    Li Y; Jia L; Ren D; Liu C; Gong Y; Wang N; Zhang X; Zhao Y
    IUBMB Life; 2014 Jul; 66(7):507-18. PubMed ID: 24984960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.
    Flem-Karlsen K; McFadden E; Omar N; Haugen MH; Øy GF; Ryder T; Gullestad HP; Hermann R; Mælandsmo GM; Flørenes VA
    Mol Cancer Ther; 2020 Mar; 19(3):895-905. PubMed ID: 31871265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma.
    Li Y; Jia L; Liu C; Gong Y; Ren D; Wang N; Zhang X; Zhao Y
    Tumour Biol; 2015 Feb; 36(2):1115-27. PubMed ID: 25327287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma.
    Bi S; Wang C; Li Y; Zhang W; Zhang J; Lv Z; Wang J
    Tumour Biol; 2017 May; 39(5):1010428317699796. PubMed ID: 28468579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
    Gjerdrum C; Tiron C; Høiby T; Stefansson I; Haugen H; Sandal T; Collett K; Li S; McCormack E; Gjertsen BT; Micklem DR; Akslen LA; Glackin C; Lorens JB
    Proc Natl Acad Sci U S A; 2010 Jan; 107(3):1124-9. PubMed ID: 20080645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Local interstitial delivery of z-butylidenephthalide by polymer wafers against malignant human gliomas.
    Harn HJ; Lin SZ; Lin PC; Liu CY; Liu PY; Chang LF; Yen SY; Hsieh DK; Liu FC; Tai DF; Chiou TW
    Neuro Oncol; 2011 Jun; 13(6):635-48. PubMed ID: 21565841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration.
    Duijkers FA; Meijerink JP; Pieters R; van Noesel MM
    Gene; 2013 May; 521(1):62-8. PubMed ID: 23523856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
    Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
    Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
    Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
    Liu R; Gong M; Li X; Zhou Y; Gao W; Tulpule A; Chaudhary PM; Jung J; Gill PS
    Blood; 2010 Jul; 116(2):297-305. PubMed ID: 20442363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
    Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
    Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.